Company
Headquarters: Lianyungang, China
Employees: 6,452
CN¥7.63 Billion
CNY as of Jan. 1, 2025
US$1.05 Billion
| Company | Market Cap (USD) |
|---|---|
| Lilly | $689.42 B |
| Novo Nordisk | $622.07 B |
| UnitedHealth Group | $487.54 B |
| Johnson & Johnson | $353.05 B |
| AbbVie | $301.60 B |
Jiangsu Kanion Pharmaceutical Co.,Ltd. researches and develops, produces, and sells Chinese medicines. It offers medicines in the fields of gynecology, orthopedics, antiviral, cardio cerebrovascular, and other fields. The company was founded in 1975 and is based in Lianyungang, China.
| Last Financial Reports Date | Sept. 30, 2024 |
| Revenue TTM | CN¥4.48 B |
| EBITDA | CN¥516.9 M |
| Gross Profit TTM | CN¥3.34 B |
| Profit Margin | 12.15% |
| Operating Margin | 8.50% |
| Quarterly Revenue Growth | -9.90% |
Jiangsu Kanion Pharmaceutical Co.,Ltd. has the following listings and related stock indices.
Stock: SSE: 600557 wb_incandescent